Provision of treatment for multiple sclerosis

Comment

A Compston. Lancet. 1999.

. 1999 May 15;353(9165):1710-1.

doi: 10.1016/S0140-6736(05)77022-7.

Erratum in

No abstract available

Interferon beta in multiple sclerosis.
Napier JC. Napier JC. Lancet. 1999 Aug 7;354(9177):512; author reply 512-3. doi: 10.1016/S0140-6736(05)75543-4. Lancet. 1999. PMID: 10465197 No abstract available.
Interferon beta in multiple sclerosis.
Gross M. Gross M. Lancet. 1999 Aug 7;354(9177):512; author reply 512-3. doi: 10.1016/S0140-6736(05)75544-6. Lancet. 1999. PMID: 10465198 No abstract available.

Interferon beta therapy for multiple sclerosis.
Goodkin DE. Goodkin DE. Lancet. 1998 Nov 7;352(9139):1486-7. doi: 10.1016/S0140-6736(98)00057-9. Lancet. 1998. PMID: 9820292 Clinical Trial. No abstract available.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
[No authors listed] [No authors listed] Lancet. 1998 Nov 7;352(9139):1491-7. Lancet. 1998. PMID: 9820296 Clinical Trial.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
[No authors listed] [No authors listed] Lancet. 1998 Nov 7;352(9139):1498-504. Lancet. 1998. PMID: 9820297 Clinical Trial.
Interferon beta in multiple sclerosis.
Napier JC. Napier JC. Lancet. 1999 Aug 7;354(9177):512; author reply 512-3. doi: 10.1016/S0140-6736(05)75543-4. Lancet. 1999. PMID: 10465197 No abstract available.